BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (TSX VENTURE:IXS) (OTCBB:IXSBF), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, is pleased to announce that it has been selected as one of the 2007 TSX Venture 50, a ranking of the top 10 public venture capital companies in five industry sectors listed on the TSX Venture Exchange.
